440 related articles for article (PubMed ID: 15472782)
21. [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample].
Escobar R; Soutullo C; San Sebastián J; Fernández E; Julián I; Lahortiga F
Actas Esp Psiquiatr; 2005; 33(1):26-32. PubMed ID: 15704028
[TBL] [Abstract][Full Text] [Related]
22. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.
Simpson D; Plosker GL
Drugs; 2004; 64(2):205-22. PubMed ID: 14717619
[TBL] [Abstract][Full Text] [Related]
23. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
; Bangs ME; Emslie GJ; Spencer TJ; Ramsey JL; Carlson C; Bartky EJ; Busner J; Duesenberg DA; Harshawat P; Kaplan SL; Quintana H; Allen AJ; Sumner CR
J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):407-20. PubMed ID: 17822337
[TBL] [Abstract][Full Text] [Related]
25. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
Wang Y; Zheng Y; Du Y; Song DH; Shin YJ; Cho SC; Kim BN; Ahn DH; Marquez-Caraveo ME; Gao H; Williams DW; Levine LR
Aust N Z J Psychiatry; 2007 Mar; 41(3):222-30. PubMed ID: 17464703
[TBL] [Abstract][Full Text] [Related]
26. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
Newcorn JH; Spencer TJ; Biederman J; Milton DR; Michelson D
J Am Acad Child Adolesc Psychiatry; 2005 Mar; 44(3):240-8. PubMed ID: 15725968
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
Buitelaar JK; Michelson D; Danckaerts M; Gillberg C; Spencer TJ; Zuddas A; Faries DE; Zhang S; Biederman J
Biol Psychiatry; 2007 Mar; 61(5):694-9. PubMed ID: 16893523
[TBL] [Abstract][Full Text] [Related]
29. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine.
Sangal RB; Sangal JM
Clin Neurophysiol; 2005 Mar; 116(3):640-7. PubMed ID: 15721078
[TBL] [Abstract][Full Text] [Related]
30. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
31. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
Simpson D; Plosker GL
CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
[TBL] [Abstract][Full Text] [Related]
32. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
33. Emotional dysregulation in adult ADHD and response to atomoxetine.
Reimherr FW; Marchant BK; Strong RE; Hedges DW; Adler L; Spencer TJ; West SA; Soni P
Biol Psychiatry; 2005 Jul; 58(2):125-31. PubMed ID: 16038683
[TBL] [Abstract][Full Text] [Related]
34. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
[TBL] [Abstract][Full Text] [Related]
35. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
36. [The effectiveness of atomoxetine in children, adolescents, and adults with ADHD. A systematic overview].
Sevecke K; Battel S; Dittmann RW; Lehmkuhl G; Döpfner M
Nervenarzt; 2006 Mar; 77(3):294, 297-300, 302-4 passim. PubMed ID: 16133434
[TBL] [Abstract][Full Text] [Related]
37. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
Spencer TJ; Sallee FR; Gilbert DL; Dunn DW; McCracken JT; Coffey BJ; Budman CL; Ricardi RK; Leonard HL; Allen AJ; Milton DR; Feldman PD; Kelsey DK; Geller DA; Linder SL; Lewis DW; Winner PK; Kurlan RM; Mintz M
J Atten Disord; 2008 Jan; 11(4):470-81. PubMed ID: 17934184
[TBL] [Abstract][Full Text] [Related]
38. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
Allen AJ; Kurlan RM; Gilbert DL; Coffey BJ; Linder SL; Lewis DW; Winner PK; Dunn DW; Dure LS; Sallee FR; Milton DR; Mintz MI; Ricardi RK; Erenberg G; Layton LL; Feldman PD; Kelsey DK; Spencer TJ
Neurology; 2005 Dec; 65(12):1941-9. PubMed ID: 16380617
[TBL] [Abstract][Full Text] [Related]
39. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder.
Newcorn JH; Sutton VK; Zhang S; Wilens T; Kratochvil C; Emslie GJ; D'souza DN; Schuh LM; Allen AJ
J Am Acad Child Adolesc Psychiatry; 2009 Dec; 48(12):1165-72. PubMed ID: 19858759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]